Strota/ Newsroom/ 2026-07-12

MANKIND (Mankind Pharma Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-12 · 11 Jul 13:28 · MANKIND stock page →

Mankind Pharma Limited has informed the Exchange about Acquisition Historically, acquisition / m&a events have moved MANKIND-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Mankind Pharma Ltd. informed the National Stock Exchange of India on 11 July 2026 that it has executed an acquisition, according to the exchange filing. The healthcare company disclosed the transaction through an outcome document filed at 13:28, marking the second such filing in as many days.

Events like this — acquisition announcements by listed Indian companies — have historically shown a 48.9% win rate across 141 comparable instances, with a net edge of 0.213%, according to Strota's base rate data. This means slightly fewer than half of such events produced positive returns in the subsequent period, with marginal average outperformance. The base rate describes past patterns across many stocks, not a forecast for Mankind Pharma specifically.

The stock closed at ₹2,525.1 on 10 July, trading 7.05% below its 52-week high of ₹2,716.5 and 32.22% above its 52-week low of ₹1,909.7. It remains above both its 50-day and 200-day simple moving averages, with a 14-day relative strength index of 58.1. The company commands a market capitalisation of ₹1,04,286 crore, trades at a price-to-earnings ratio of 54.64, and carries a dividend yield of 0.08%. In the derivatives segment, open interest rose 5.09% on 12 July even as the price slipped 0.22%, classified as a "Short Buildup" pattern where traders are adding bearish positions.

The filing confirms an acquisition has occurred; it does not specify the target, consideration, or strategic rationale. The data establishes what has been reported and how similar events have performed historically, not whether this particular transaction will benefit shareholders.

The catalyst

Mankind Pharma Limited has informed the Exchange about Acquisition (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

MANKIND right now

trading -0.36% on the day; F&O shows Short Buildup (OI 5.09% ); P/E 54.64; RSI 58.1. Full MANKIND analysis →

Sources

Mankind Pharma Limited has informed the Exchange about Acquisition — NSE
Mankind Pharma Shares In Focus As InCred Initiates Coverage, Eyes 11% Upside — Check Target Price — NDTV Profit
Mankind Pharma Ltd. Actuals & Estimates (NSE:MANKIND) — TradingView
MANKIND Forecast — Price Target — Prediction for 2027 — TradingView
Piramal Pharma, Cohance Lifesciences, Sun Pharma, Cipla, Dr Reddy's, other pharma shares jump; what's driving the rally? — Business Today

Keep digging

MANKIND — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.